-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105

Benzinga·09/08/2026 12:11:30
Listen to the news
BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.